Abstract: The invention relates to a liquid pharmaceutical composition of aldesleukin/SDS aggregates and its use in the treatment of auto-immune disease, inflammatory disorders and cancer. A method for preparing said composition is also described.

Abstract: Cell culture media, preservative media or cryopreservation media include a low dose of one or more cytokines, e.g. interleukin-2 (IL-2).

Abstract: The invention relates to a liquid pharmaceutical composition of aldesleukin/SDS aggregates and its use in the treatment of auto-immune disease, inflammatory disorders and cancer. A method for preparing said composition is also described.

Abstract: The invention refers to a method for preparing novel and powerful regulatory B cells (Breg-nov) by contacting cells obtained from the immune system with phosphorothioate oligonucleotide. Methods of suppressing-autoimmunity or suppressing acute or chronic inflammation or repairing a damaged organ or tissue in mammals, including humans, by administering to the mammals in need, Breg-nov cells obtained as herein described.

Abstract: Cryopreservation media which include additives for cryopreservation of biological samples which maintain viability even after multiple freeze-thaw cycles.

Abstract: Compositions for maintaining cellular integrity especially in cases of cryopreservation and multiple freeze/thawing cycles are provided. In addition, the compositions can be used in various media for a variety of applications.

Abstract: Compositions for maintaining cellular integrity especially in cases of cryopreservation and multiple freeze/thawing cycles are provided. In addition, the compositions can be used in various media for a variety of applications.

Abstract: Sequences having specificity for Mycoplasma and related Mollicutes genus strains and uses thereof. Methods of use include detection of samples contaminated with Mycoplasma. Kits are provided and comprise one or more oligonucleotides for the detection of Mycoplasma and related Mollicutes genus strains.

Abstract: Sequences having specificity for Mycoplasma and related Mollicutes genus strains and uses thereof. Methods of use include detection of samples contaminated with Mycoplasma. Kits are provided and comprise one or more oligonucleotides for the detection of Mycoplasma and related Mollicutes genus strains.

Abstract: Cryopreservative compositions include a carboxylated-polyamino acid, and at least one of an organic amphoteric agent or a polysaccharide. Methods of cryopreservation are also provided.

Abstract: Matrix metalloproteinases (MMPs) compositions, inactive forms of MMPs (e.g. proMMPs), fragments, mutants, variants or combinations thereof. A pharmaceutical composition comprises one or more of the above in a pharmaceutical carrier. A composition comprises at least one of: a matrix metalloproteinase (MMP), an inactive MMP or a proenzyme (proMMP) thereof, wherein the matrix metalloproteinase (MMPs), inactive MMPs or proMMPs thereof, comprise: MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-11, MMP-12, MMP-13.MMP-14, MMP-15, MMP-16, MMP-17, MMP-18, MMP-19, MMP-20, MMP-21, MMP-23A, MMP-23B, MMP-24, MMP-25, MMP-26, MMP-27, MMP-28, active fragments, mutants, variants or any combinations thereof. The uses include isolation of cells, in particular stem cells, from tissues, dissociation of tissues, proteins and treatment of a variety of conditions.

Abstract: Sequences having specificity for Mycoplasma and related Mollicutes genus strains and uses thereof. Methods of use include detection of samples contaminated with Mycoplasma. Kits are provided and comprise one or more oligonucleotides for the detection of Mycoplasma and related Mollicutes genus strains.

Abstract: A blood collection device includes a collection container, a flexible conduit permanently affixed at a proximal end to the collection container, and a needle permanently affixed to a distal end of the flexible conduit. The collection container, flexible conduit and needle can be provided within a package. A method for collecting blood products is also disclosed.

Abstract: A method for collecting and storing biological material includes the steps of obtaining a patient identity of a patient and a biological material from a patient. A DNA identity analysis is performed to establish a DNA identity for the patient. The DNA identity is associated with the patient identity and the biological material. The biological material is stored in a preserving environment, and the patient identity and the DNA identity are stored in a database. A request for the biological material is received from a requestor purporting to have the patient identity. A DNA sample from said requestor is obtained. A DNA identity analysis is performed on the DNA sample from the requestor to obtain a DNA identity of the requestor. The DNA identity of the requestor is then compared to the stored DNA identity of the patient, and if the DNA identities match, the biological material is provided to the requestor.